Liver Cancer Therapeutics Market Global Recent Trend, Industry Size, Share, Merger, Strategy Profiling, Growing CAGR Value, Technology Advancement Future Growth Insights by 2026
SEATTLE, March 25, 2021, (PHARMIWEB) — Liver cancer is a cancer that begins in the cells of liver when there is an uncontrolled growth of cells. It is a type of malignant hepatic tumor in or on the liver, which may cause due to excessive alcohol intake, diabetes, certain inherited liver diseases, and hepatitis. Its symptoms do not appear until it is in advance stage, however, loss of weight without trying, abdominal swelling, white & chalky stools, nausea and vomiting, and fatigue are some of its common symptoms. The most common type of liver cancer is hepatocellular carcinoma, which begins in the main type of liver cell.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1591
Other types of liver cancer such as hepatoblastoma and intrahepatic cholangiocarcinoma are less common. Incidence rate of liver cancer is high in the U.S., owing to prevalence of cirrhosis caused by nonalcoholic fatty liver disease and chronic hepatitis C. According to American Cancer Society 2017, Liver cancer is the 10th most common cancer and fifth most common cause of death among men in the U.S. Moreover, it is the eighth most common cause of death among women. Colorectal cancer is expected to be one of the precursor for liver cancer. According to International Scholarly Research Network, a clinical study on Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer in 2012: Efficacy and Feasibility with Survival and Cost-Effectiveness Observations, around 50% of the patient suffering from colorectal cancer develop liver cancer.
Market Dynamics- Driver
Increasing research and development activities to identify case of cancer is expected to drive growth of the global liver cancer therapeutics market during the forecast period. For instance, in November, 2014, researchers at the San Diego School of Medicine and University of California found that long-term exposure to triclosan, a common ingredient in detergents and soaps, causes liver fibrosis and cancer in laboratory mice. However, triclosan has not been proven to cause liver cancer in human and it is currently under examination by the U.S. Food and Drug Administration (FDA) to determine whether it has negative health impacts.
Exclusive offer!!! Purchase the report at a discounted rate!!!
Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount
Quick Buy – Liver Cancer Therapeutics Market Research Report: https://bit.ly/3vXCJ66
Moreover, increasing prevalence of liver cancer in various regions is expected to propel the global liver cancer therapeutics market growth over the forecast period. For instance, according to Cancer Research UK, around 5,736 new cases of liver cancer were reported in UK in 2015. Furthermore, according to cancer organization, around 40,710 new cases of liver cancer was diagnosed in the U.S. during 2017, three of which will be hepatocellular carcinoma (HCC).
Furthermore, key players in the market are involved in various growth strategies such as collaboration and agreement, in order to gain competitive edge in the market. For instance, in 2013, Roche and Inovio Pharmaceuticals, Inc. entered into license agreement to research, develop and commercialize Inovio’s highly-optimized, multi-antigen DNA immunotherapies targeting hepatitis B and prostate cancer. It has also been shown that liver cancer risk increases substantially with the increase in Body Mass Index (BMI) of an individual. More than half of the adult population in the U.S. is overweight, which is propelling demand for therapeutic drugs of liver cancer, which in turn is creating opportunities for manufacturers.
Market Dynamics- Restraints
Strict regulatory policies for drug approval and high cost of drugs is expected to restrain growth of the global liver cancer therapeutics market over the forecast period. For instance, in March 2017, ArQule, Inc.’s product- tivantinib did not clear phase 3 clinical trial for hepatocellular carcinoma (HCC) in japan, as it did not meet its primary endpoint of progression free survival (PFS).
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/1591
Geographically, global liver cancer therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Among regions, North America is expected to hold dominant position in the global liver cancer therapeutics market over the forecast period. This is owing to increasing funding for research and development activities by government. American Liver Foundation is an organization that promote education, support and research for the prevention, treatment, and cure of liver disease and since 1979, this organization has provided more than US$ 26 million in research funding. Furthermore, liver cancer is more common in economies of Sub-Saharan Africa and Southeast Asia as compared to the U.S. According to GLOBOCAN, in 2012, around 83% (50% in China alone) of the estimated 782,000 new cancer cases were reported worldwide. Moreover, in Sub Saharan African countries, the risk of developing cancer and death from the same is high, owing to the late stage diagnosis and lack of treatment, which is driving growth of the liver cancer therapeutics market.
Major companies operating in the global liver cancer therapeutics market are Bayer AG, Bristol-Myers Squibb Company, Onyx Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Jennerex Biotherapeutics Inc., and Celsion Corp.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/liver-cancer-therapeutics-market-1591
Global Liver cancer therapeutics Market – Taxonomy
By Drug Class
- Targeted Therapy
- Sorafenib (Nexavar)
- Regorafenib (Stivarga)
- Nivolumab (Opdivo)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Table of Content
Global Liver Cancer Therapeutics Market Research Report
Section 1: Global Liver Cancer Therapeutics Industry Overview
Section 2: Global Economic Impact on Liver Cancer Therapeutics Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Liver Cancer Therapeutics Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Liver Cancer Therapeutics Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire